Uncategorized

Farewell CFC Albuterol Inhalers…

Effective December 31, 2008, Albuterol inhalers using chlorofluorocarbon (CFC) propellants will no longer be available.  They have been banned as part of the Clean Air Act and Montreal Protocol on Substances that Deplete the Ozone Layer.  The supply has already tightened and the CFC inhalers’ days are numbered. Please note that no CFC-propelled inhalers may be produced, marketed or sold after December 31, 2008. 

Many clinics offering pharmaceutical dispensing to their patients are looking for effective alternatives.  The FDA has released a list of approved alternatives that use hydrofluoroalkane (HFA) propellant.  Please note that Albuterol is still available; it is simply the chemicals used to spray the medication into the lungs that is in question. 

You can get detailed information on alternatives at this link.  We have seen many of our clinics purchasing Ventolin as a replacement.  Although we haven’t had a lot of direct feedback yet, this seems to be the most cost-effective alternative.  You can call PCA Pharmaceuticals at 800.722.0772 to get pricing.

If you want some hardcore clinical data, I found a study that compares HFA Ventolin with CFC Ventolin. The short version: the study concludes that the two are “clinically comparable.”

For more information, go to http://www.fda.gov/Cder/mdi/albuterol.htm

Schedule a free claims analysis now.

Let’s Talk now

TONY PURKEY JOINS NORTHWIND AS SENIOR VICE PRESIDENT, CLIENT STRATEGIES

Betsy Bigler | Mar 7th, 2024
INDIANAPOLIS, March 7, 2024 – Northwind has announced the addition of Tony Purkey as Senior Vice President, Client Strategies. “Demand from our self-funded employer and union clients is driving rapid growth,” said Phillip Berry, CEO. “Tony Purkey joins Northwind at a time when we need high-integrity leaders with expert knowledge in employer-sponsored health and the … more »

continue reading

Voices Lost in the Noise

Phillip Berry | Jan 31st, 2024
In the health benefits world, the mad scramble toward January renewals/starts has subsided and attention has turned to the annual cycle of review necessary to gauge progress. How did we do? The plan review process generally centers on analytics to gauge progress or regress and to identify “areas of opportunity.” Good. The right data with … more »

continue reading